illudalic acid: isolated from Clitocybe illudens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3653077 |
| CHEMBL ID | 506661 |
| SCHEMBL ID | 24228643 |
| MeSH ID | M0526503 |
| Synonym |
|---|
| bdbm50262987 |
| CHEMBL506661 , |
| illudalic acid |
| 3,6-dihydroxy-8,8-dimethyl-1-oxo-3,4,7,9-tetrahydrocyclopenta[h]isochromene-5-carbaldehyde |
| gtpl8770 |
| 18508-77-5 |
| unii-hw3u676a69 |
| 3,6-dihydroxy-8,8-dimethyl-1-oxo-1,3,4,7,8,9-hexahydro-cyclopenta(h)isochromene-5-carbaldehyde |
| cyclopenta(h)-2-benzopyran-5-carboxaldehyde, 1,3,4,7,8,9-hexahydro-3,6-dihydroxy-8,8-dimethyl-1-oxo- |
| 1,3,4,7,8,9-hexahydro-3,6-dihydroxy-8,8-dimethyl-1-oxocyclopenta(h)-2-benzopyran-5-carboxaldehyde |
| hw3u676a69 , |
| illudalate |
| Q27078041 |
| SCHEMBL24228643 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Receptor-type tyrosine-protein phosphatase C | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.3000 | 2.7571 | 10.0000 | AID1617803 |
| Receptor-type tyrosine-protein phosphatase F | Homo sapiens (human) | IC50 (µMol) | 1.7000 | 1.3000 | 2.6660 | 4.2300 | AID1617804; AID342510 |
| Tyrosine-protein phosphatase non-receptor type 2 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.7000 | 4.5804 | 9.4500 | AID1617801 |
| Dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 4.0000 | 5.9750 | 8.5000 | AID1617798 |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | IC50 (µMol) | 29.0000 | 0.3180 | 4.0042 | 9.6000 | AID1617814 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1617801 | Inhibition of TCPTP (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID342510 | Inhibition of human recombinant LAR | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Illudalic acid as a potential LAR inhibitor: synthesis, SAR, and preliminary studies on the mechanism of action. |
| AID1617806 | Inhibition of PTPep (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617796 | Covalent inhibition of LAR (unknown origin) using DiFMUP as substrate assessed as fast inactivation constant incubated for 15 to 120 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617794 | Inhibition of LAR (unknown origin) assessed as time required for half of the protein to be covalently modified using DiFMUP as substrate incubated for 15 to 120 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence | |||
| AID1617808 | Inhibition of HePTP (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617809 | Inhibition of TCPTP (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617811 | Inhibition of SHP2 (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617810 | Inhibition of PTPmu (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617814 | Inhibition of SHP2 (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617795 | Non-covalent inhibition of LAR (unknown origin) using DiFMUP as substrate incubated for 15 to 120 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617815 | Time-dependent inhibition of LAR (unknown origin) using DiFMUP as substrate at 1 uM incubated for 15 to 120 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617804 | Inhibition of LAR (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617813 | Inhibition of LAR (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617798 | Inhibition of VHR (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617803 | Inhibition of CD45 (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617812 | Inhibition of CD45 (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617800 | Inhibition of PTPep (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617819 | Ratio of Kinact to Ki for LAR (unknown origin) using DiFMUP as substrate incubated for 15 to 120 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617807 | Inhibition of VHR (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617818 | Time-dependent inhibition of PTPmu (unknown origin) using DiFMUP as substrate at 10 uM incubated for 5 to 120 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617802 | Inhibition of PTPmu (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617799 | Inhibition of HePTP (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617805 | Inhibition of LMWPTP (unknown origin) using DiFMUP as substrate at 100 uM incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617817 | Time dependent inhibition of CD45 (unknown origin) using DiFMUP as substrate at 10 uM incubated for 5 to 120 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1617797 | Inhibition of LMWPTP (unknown origin) using DiFMUP as substrate incubated for 30 mins followed by substrate addition at pH 6.5 by standard phosphatase assay based fluorescence analysis | |||
| AID1345593 | Human RTP Type F (Receptor tyrosine phosphatase (RTP) family) | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | Illudalic acid as a potential LAR inhibitor: synthesis, SAR, and preliminary studies on the mechanism of action. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||